Emadine (Emedastine) Eye Drops
Antihistamine eye drops for seasonal allergic conjunctivitis
Quick Facts About Emadine
Key Takeaways About Emadine
- Targeted allergy relief: Emadine is a selective H1 antihistamine eye drop specifically designed to treat seasonal allergic conjunctivitis by blocking histamine at the site of the allergic reaction in the eye
- Simple dosing: One drop in each affected eye twice daily is the standard dose for adults and children over 3 years of age
- Contact lens warning: Remove contact lenses before applying Emadine and wait at least 15 minutes before reinserting them, as the preservative benzalkonium chloride can damage soft lenses
- Limited age groups: Emadine is not recommended for children under 3 years, adults over 65 years, or patients with impaired kidney or liver function due to insufficient clinical data
- Short shelf life after opening: Discard the bottle 4 weeks after first opening to prevent contamination and infection
What Is Emadine and What Is It Used For?
Emadine is a prescription antihistamine eye drop containing emedastine difumarate. It is used to treat seasonal allergic conjunctivitis, an allergic condition of the eye caused by allergens such as pollen, dust mites, and animal dander. Emadine works by reducing the intensity of the allergic reaction in the conjunctiva.
Allergic conjunctivitis is one of the most common eye conditions worldwide, affecting an estimated 15-40% of the population. It occurs when the conjunctiva, the thin transparent membrane covering the white of the eye and the inner surface of the eyelids, becomes inflamed due to an allergic response. Common triggers include tree and grass pollen during spring and summer months, house dust mites, mold spores, and animal dander from pets such as cats and dogs.
When allergens come into contact with the conjunctiva in a sensitized individual, the immune system triggers a cascade of events involving the release of histamine and other inflammatory mediators from mast cells. This histamine release causes the characteristic symptoms of allergic conjunctivitis: itching, redness, tearing, and swelling of the eyes. These symptoms can range from mild discomfort to significant impairment of daily activities and quality of life.
Emadine contains the active substance emedastine (as difumarate salt) at a concentration of 0.5 mg/mL (0.05%). As a selective histamine H1 receptor antagonist, emedastine works by competitively blocking the H1 receptors on conjunctival epithelial cells and blood vessels in the eye. By preventing histamine from binding to these receptors, Emadine effectively reduces the itching, redness, and swelling associated with allergic conjunctivitis. Unlike some older antihistamines, emedastine has high selectivity for the H1 receptor, which contributes to its favorable side effect profile when used topically.
Clinical studies have demonstrated that emedastine eye drops provide rapid relief of symptoms, with onset of action typically within minutes of application. The medication has been shown to be effective in reducing the cardinal symptoms of allergic conjunctivitis, particularly ocular itching, which is often the most bothersome symptom for patients. Emadine is approved for use in the European Union and is marketed by Immedica Pharma AB.
Emadine treats the symptoms of allergic conjunctivitis but does not cure the underlying allergy. For long-term management, discuss allergen avoidance strategies and potential allergen immunotherapy with your doctor. If your symptoms do not improve or worsen while using Emadine, consult your healthcare provider.
What Should You Know Before Using Emadine?
Before using Emadine, inform your doctor if you have any known allergies, kidney or liver problems, or if you are pregnant or breastfeeding. Do not use Emadine if you are allergic to emedastine or any of its other ingredients. Remove contact lenses before application and wait at least 15 minutes before reinserting.
Contraindications
You should not use Emadine if you are allergic (hypersensitive) to emedastine or any of the other ingredients in the formulation. The inactive ingredients include benzalkonium chloride (preservative), trometamol, sodium chloride, hypromellose, and purified water. Small amounts of hydrochloric acid or sodium hydroxide may be added to maintain normal pH levels. If you are unsure whether you have an allergy to any of these components, consult your doctor or pharmacist before using Emadine.
Hypersensitivity reactions to ophthalmic medications can manifest as increased eye redness, itching, burning, or swelling after application. If you experience any of these symptoms after using Emadine and they are more severe than your usual allergic conjunctivitis symptoms, discontinue use and contact your healthcare provider immediately.
Warnings and Precautions
Several important warnings and precautions should be considered before using Emadine eye drops:
- Children under 3 years: Emadine should not be used in children younger than 3 years of age, as the safety and efficacy have not been established in this age group
- Patients over 65 years: Emadine is not recommended for patients over 65 years of age because the product has not been studied in clinical trials involving this age group
- Impaired kidney or liver function: Emadine is not recommended for patients with reduced kidney or liver function due to a lack of clinical data in these populations
- Driving and operating machinery: If you experience temporary blurred vision or other visual disturbances after applying Emadine, wait until your vision clears before driving or operating machinery
Emadine contains benzalkonium chloride (0.1 mg/mL) as a preservative. This substance can be absorbed by soft contact lenses and may cause discoloration. Remove contact lenses before applying Emadine and wait at least 15 minutes before reinserting them. Benzalkonium chloride may also be irritating to the eyes, especially if you have dry eyes or corneal problems. If you experience irritation, stinging, or pain after using the medication, contact your doctor.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, seek advice from your doctor or pharmacist before using Emadine. There is insufficient clinical data on the use of emedastine during pregnancy and breastfeeding. While topical ophthalmic medications generally have lower systemic absorption than oral medications, a healthcare professional should carefully weigh the potential benefits against the possible risks before prescribing Emadine to pregnant or breastfeeding women.
As a general principle, medications should be avoided during pregnancy and breastfeeding unless clearly necessary. If you discover that you are pregnant while using Emadine, contact your doctor to discuss whether continued treatment is appropriate for your situation.
Drug Interactions
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medications. While no specific drug interactions with Emadine have been extensively documented due to its low systemic absorption when applied topically, certain general precautions apply when using multiple ophthalmic preparations.
How Does Emadine Interact with Other Drugs?
Emadine has low systemic absorption when applied topically to the eye, which limits the potential for systemic drug interactions. However, if you use other eye drops or eye ointments simultaneously, you should wait at least 10 minutes between applications. Eye ointments should always be applied last.
Because emedastine is applied topically to the eye, the amount that reaches the systemic circulation is very small compared to oral medications. This significantly reduces the risk of interactions with other systemic medications. However, patients should always inform their healthcare providers about all medications they are using, including prescription drugs, over-the-counter medications, and herbal supplements.
When using multiple ophthalmic preparations, proper timing of administration is essential to ensure optimal absorption and effectiveness of each medication. Applying drops too close together can result in the second drop washing away the first, reducing the therapeutic effect. The general recommendation is to wait at least 10 minutes between different eye drop preparations.
| Medication Type | Interaction Level | Recommendation |
|---|---|---|
| Other antihistamine eye drops | Potential duplication | Avoid concurrent use; consult your doctor |
| Other eye drops (e.g., glaucoma, dry eye) | Timing consideration | Wait at least 10 minutes between applications |
| Eye ointments | Timing consideration | Always apply eye ointments last, after all eye drops |
| Oral antihistamines | Low risk (minimal systemic absorption) | Generally safe; inform your doctor of all medications |
| Corticosteroid eye drops | Timing consideration | Wait at least 10 minutes between applications |
If you are using other eye drops at the same time as Emadine, the recommended approach is to apply Emadine first, wait at least 10 minutes, and then apply the next medication. This waiting period allows Emadine to be adequately absorbed by the conjunctival tissues before the next drop is applied. If you also use eye ointments, these should always be applied last, as the oily base of ointments can create a barrier that prevents subsequent eye drops from being absorbed properly.
If you need to apply several different eye drops, create a schedule to ensure proper spacing. Consider setting reminders on your phone or writing down the times for each medication. Always wash your hands before applying any eye drops, and avoid touching the dropper tip to your eye or any other surface to prevent contamination.
What Is the Correct Dosage of Emadine?
The recommended dose of Emadine for adults and children over 3 years is one drop in each affected eye, twice daily. Always use Emadine exactly as your doctor has prescribed. The eye drops should only be used for instillation into the eye and not by any other route.
Emadine should be used exactly as directed by your prescribing physician. The standard dosing regimen is simple and straightforward: one drop in the affected eye(s) twice daily, typically in the morning and evening. The drops should be applied at approximately the same times each day to maintain a consistent level of medication in the eye.
Adults (18-65 years)
One drop in each affected eye, twice daily (morning and evening). Continue treatment as directed by your doctor for the duration of the allergy season.
Children (3-17 years)
One drop in each affected eye, twice daily. The dosage for children over 3 years is the same as for adults. Do not use in children under 3 years of age.
Elderly (over 65 years)
Emadine is not recommended for use in patients over 65 years of age, as the product has not been studied in clinical trials in this age group. Consult your doctor for alternative treatments.
How to Apply Emadine Eye Drops Correctly
Proper application technique is crucial for the effectiveness of Emadine and for minimizing the risk of contamination and side effects. Follow these step-by-step instructions:
- Wash your hands thoroughly with soap and water before handling the eye drop bottle
- Remove the cap from the bottle. If the safety collar is loose after removing the cap, remove it before using the product
- Hold the bottle upside down between your thumb and middle finger
- Tilt your head back and pull down your lower eyelid with a clean finger to create a small pocket between the eyelid and your eye
- Bring the bottle tip close to your eye without touching the eye, eyelid, surrounding areas, or any other surfaces with the dropper tip, as this can contaminate the drops
- Gently press the bottom of the bottle with your index finger to release one drop into the pocket. The bottle is designed so that a light press is sufficient
- Close your eye gently and press lightly on the inner corner of the eye (near the nose) for about one minute to reduce systemic absorption
- If treating both eyes, repeat the procedure for the other eye
- Replace the cap tightly on the bottle immediately after use
Missed Dose
If you forget to apply Emadine at the scheduled time, apply the missed dose as soon as you remember. Then continue with your normal dosing schedule. However, if it is almost time for your next dose, skip the missed dose and continue as usual. Do not apply a double dose to make up for a forgotten one.
Overdose
If you accidentally apply too many drops in your eye, flush the eye with clean, sterile saline solution if available, or with lukewarm water. Do not apply more drops until it is time for your next scheduled dose. If you accidentally swallow Emadine or inject it, contact a doctor immediately, as it may affect your heart rate.
If you wear contact lenses, remove them before applying Emadine and wait at least 15 minutes before reinserting. Never touch the dropper tip to any surface, including your eye, to prevent bacterial contamination of the solution. If the dropper tip becomes contaminated, discard the bottle and use a new one.
What Are the Side Effects of Emadine?
Like all medicines, Emadine can cause side effects, although not everyone experiences them. The most common side effects include eye pain, eye itching, and eye redness. Uncommon side effects include headache, blurred vision, and dry eyes. You can usually continue using the drops unless the side effects are severe.
Clinical trials and post-marketing surveillance have identified several side effects associated with Emadine use. The majority of reported side effects are local effects affecting the eyes, which is expected for a topical ophthalmic medication. Most side effects are mild to moderate in severity and are typically transient, resolving on their own without the need to discontinue treatment.
Side effects are categorized below by frequency of occurrence. If you experience any side effect that concerns you, or if a side effect becomes severe or persistent, consult your doctor or pharmacist. You can usually continue taking the drops unless the side effects are serious.
Common Side Effects
May affect up to 1 in 10 users
- Eye pain at the application site
- Eye itching (ocular pruritus)
- Eye redness (ocular hyperemia)
Uncommon Side Effects
May affect up to 1 in 100 users
- Eye effects: Corneal disorders, abnormal sensation in the eye, increased tear production, tired eyes, eye irritation, blurred vision, corneal staining, dry eyes
- General effects: Headache, sleep problems (insomnia), sinus headache, bad taste in the mouth (dysgeusia), skin rash
Frequency Not Known
Cannot be estimated from available data
- Increased heart rate (tachycardia)
The most frequently reported side effect in clinical trials was mild, transient eye discomfort at the application site. This typically occurs immediately after instillation and resolves within minutes. Eye redness and itching, while also reported as side effects, should be distinguished from the symptoms of the underlying allergic conjunctivitis being treated. If your eye symptoms worsen after starting Emadine rather than improve, this may indicate a reaction to the medication itself rather than a treatment failure, and you should consult your doctor.
Corneal effects, including corneal staining and corneal disorders, are uncommon but should be monitored during treatment. These may be related to the preservative benzalkonium chloride, which is known to have a drying effect on the ocular surface, particularly with prolonged use. Patients with pre-existing dry eye disease or corneal conditions may be more susceptible to these effects.
The systemic side effects (headache, sleep disturbance, sinus headache, taste disturbance, and skin rash) are uncommon and likely result from small amounts of emedastine being absorbed into the systemic circulation. Pressing gently on the inner corner of the eye after application can help minimize systemic absorption and reduce the likelihood of these side effects.
Contact your doctor immediately if you experience a severe allergic reaction to Emadine, which may include swelling of the face, lips, tongue, or throat, difficulty breathing, or severe skin rash. Also seek prompt medical attention if you develop persistent or worsening eye pain, sudden vision changes, or signs of eye infection such as discharge or crusting. If you notice an increased heart rate after using Emadine, inform your healthcare provider.
Reporting Side Effects
It is important to report suspected side effects after a medicine has been authorized. This makes it possible to continuously monitor the benefit-risk balance of the medicine. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national pharmacovigilance authority. In the EU, adverse reactions can also be reported via the European Medicines Agency (EMA) reporting system.
How Should You Store Emadine?
Store Emadine at or below 25°C (77°F). Keep the bottle tightly closed when not in use. Discard the bottle 4 weeks after first opening to prevent contamination. Keep out of the sight and reach of children. Do not use after the expiration date.
Proper storage of Emadine is essential to maintain the medication's effectiveness and prevent contamination that could lead to eye infections. Ophthalmic solutions are particularly susceptible to microbial contamination once opened, which is why strict adherence to storage guidelines is critical for patient safety.
- Temperature: Store at or below 25°C (77°F). Do not freeze the eye drops
- After opening: Discard the bottle 4 weeks (28 days) after first opening, regardless of how much solution remains. Write the date you opened the bottle on the label or carton to help you remember
- Expiration date: Do not use after the expiration date (EXP) printed on the bottle and carton. The expiration date refers to the last day of the stated month
- Keep out of reach: Store out of the sight and reach of children
- Keep the bottle tightly closed: Replace the cap immediately after each use to prevent contamination
The 4-week discard period after opening is a standard precaution for preserved ophthalmic solutions. Even though Emadine contains benzalkonium chloride as a preservative, the risk of microbial contamination increases with repeated opening and closing of the bottle. Using an eye drop solution beyond the recommended period after opening may expose you to harmful microorganisms that could cause serious eye infections, including bacterial keratitis.
Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help protect the environment and ensure that unused medications do not pose a risk to others.
What Does Emadine Contain?
The active substance in Emadine is emedastine 0.5 mg/mL (as difumarate). Inactive ingredients include benzalkonium chloride (preservative), trometamol, sodium chloride, hypromellose, and purified water. The solution is supplied in a 5 mL plastic bottle with a screw cap.
Understanding the composition of your medication can help you identify potential allergens and understand how the product works. Emadine is formulated as a clear, sterile ophthalmic solution designed for comfortable application to the eye.
| Ingredient | Role | Details |
|---|---|---|
| Emedastine difumarate | Active ingredient | 0.5 mg/mL; selective H1 antihistamine |
| Benzalkonium chloride | Preservative | 0.1 mg/mL; antimicrobial agent |
| Trometamol | Buffer | Maintains proper pH of solution |
| Sodium chloride | Tonicity agent | Ensures solution is isotonic with tears |
| Hypromellose | Viscosity enhancer | Improves ocular surface retention time |
| Purified water | Solvent | Vehicle for the active and inactive ingredients |
| Hydrochloric acid / Sodium hydroxide | pH adjustment | Small amounts added to maintain normal acidity |
Emadine is supplied as a liquid solution in a package containing one 5 mL plastic bottle (Drop-Tainer) with a screw cap. The bottle is designed to deliver consistent drop sizes with gentle pressure, making application straightforward. The solution should be clear and free from particles. Do not use the solution if it appears cloudy, discolored, or contains visible particles.
The marketing authorization holder is Immedica Pharma AB, based in Stockholm, Sweden. The product is manufactured by S.A. Alcon-Couvreur N.V. in Puurs, Belgium, and Siegfried El Masnou, S.A. in Barcelona, Spain. The product information was last updated in February 2025. Additional information about Emadine is available on the European Medicines Agency (EMA) website.
Frequently Asked Questions About Emadine
Medical References
All information in this article is based on authoritative medical sources and regulatory documents. References are listed below for transparency and verification.
- European Medicines Agency (EMA). "Emadine: EPAR - Product Information." EMA Product Page Official European regulatory documentation for Emadine, including Summary of Product Characteristics.
- Abelson MB, Chambers WA, Smith LM. (1990). "Conjunctival allergen challenge: A clinical approach to studying allergic conjunctivitis." Archives of Ophthalmology. 108(1):84-88. Foundational research on allergic conjunctivitis challenge models used in clinical trials of antihistamine eye drops.
- Bielory L, Friedlaender MH. (2008). "Allergic conjunctivitis." Immunology and Allergy Clinics of North America. 28(1):43-58. Comprehensive review of allergic conjunctivitis pathophysiology and treatment, including topical antihistamines.
- Leonardi A, et al. (2019). "Allergic conjunctivitis: A comprehensive review of diagnosis and treatment." European Journal of Ophthalmology. 29(4):331-340. Updated review of diagnostic and therapeutic approaches to allergic conjunctivitis.
- World Health Organization (WHO). "Model List of Essential Medicines." WHO Essential Medicines WHO global guidance on essential ophthalmic medicines.
- British National Formulary (BNF). "Emedastine." BNF Online UK prescribing reference for emedastine, including dosage and safety information.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Drug information is sourced from EMA-approved Summary of Product Characteristics and peer-reviewed literature.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in ophthalmology, pharmacology, and internal medicine.